Zura Bio’s (ZURA) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

A number of other analysts have also issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Chardan Capital reduced their price target on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 8th. Finally, Leerink Partners began coverage on shares of Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $15.80.

Zura Bio Stock Performance

Shares of Zura Bio stock opened at $2.67 on Tuesday. The firm has a fifty day simple moving average of $3.43 and a 200-day simple moving average of $3.65. Zura Bio has a 1-year low of $2.00 and a 1-year high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Equities research analysts anticipate that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its holdings in shares of Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after buying an additional 5,900 shares in the last quarter. Bank of New York Mellon Corp grew its position in Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares during the period. Forefront Analytics LLC raised its stake in Zura Bio by 22.1% during the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after acquiring an additional 7,531 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Zura Bio during the third quarter valued at $46,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Zura Bio in the 2nd quarter valued at $43,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.